{
  "pmcid": "10766409",
  "sha256": "0f5212c74940348221d81ff42902b21fd2efc2ef3c71207b4926d7c038368f1a",
  "timestamp_utc": "2025-11-09T21:56:47.228353+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.526673286991063,
    "reading_ease": 32.29558589870905,
    "word_count": 212
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "The POWER Trial: A Randomised Controlled Trial on Pre-Operative Endocrine Therapy in Early-Stage Breast Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This randomised controlled trial was conducted at [study setting]."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were older women with early-stage, ER-positive breast cancer."
      },
      "Intervention": {
        "score": 2,
        "evidence": "The intervention group received pre-ET, while the control group did not."
      },
      "Objective": {
        "score": 1,
        "evidence": "investigates whether 3 months of pre-operative endocrine therapy (pre-ET) informs adjuvant radiation therapy decisions in older women with early-stage, ER-positive breast cancer."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in Ki-67 expression, measured over 3 months."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was performed using [randomisation method] with allocation concealment by [method]."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Thirty-seven participants completed pre-ET and surgery."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Ki-67 expression decreased from 13% to 5% (p<0.001), and cellularity decreased from 40% to 23% (p<0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT04272801"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}